The severe EPS miss and minimal cash runway (into Sep 2026) despite a $10M PIPE signal high dilution risk and potential need for additional capital. Traders should watch for the NEO100 interim data readout (~Aug 2026) as a binary catalyst, but the near-term financial fragility and lack of revenue make this a high-risk speculative name. The CEO's insider purchase provides some confidence but does not offset the fundamental cash burn.
Price Chart
Executive Summary
NeOnc reported Q1 2026 EPS of -$0.38, a 245.5% miss vs consensus of -$0.11, with zero revenue. The net loss improved YoY to $8.8M from $32.3M due to lower non-cash stock-based compensation, but cash burn remains high at ~$6.1M/quarter. The company highlighted a $10M PIPE from Cinctive Capital and an undrawn $10M line of credit, funding operations into September 2026, while advancing NEO212 and NEO100 clinical programs with an interim readout expected in August 2026.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.38 missed consensus of -$0.11 by 245.5%
- Zero revenue reported; clinical-stage biopharma with no approved products
- Net loss improved to $8.8M from $32.3M YoY, driven by lower non-cash stock-based compensation
- Cash and cash equivalents of $138,601 as of March 31, 2026; plus $10M PIPE and $10M undrawn line of credit expected to fund operations into September 2026
- Normalized cash operating expenses of ~$6.1M/quarter (~$24.4M annualized)
- NEO212 Phase 1 complete; RP2D set at 610 mg; planning Type B End-of-Phase 1 FDA meeting
- NEO100 Phase 2a fully enrolled; interim data readout expected ~August 2026
- CEO purchased >$500K of shares in open market
- Appointed David Choi as Chief Accounting Officer
Financial Impact
EPS miss of -$0.27 vs consensus; net loss of $8.8M; cash runway only into September 2026 despite PIPE
Risk Factors
- Cash runway only into September 2026; likely need for additional dilutive financing
- No revenue; clinical-stage with no approved products
- NEO212 and NEO100 clinical data may fail to meet endpoints
- High cash burn rate of ~$24.4M annualized relative to current cash position
- Stock-based compensation remains significant at $2.7M/quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $3.27 | awaiting T+60 | — | $2.94 (−10.17%) |
Oct 15, 2026 11d ago | 8-K | $2.70 | awaiting T+60 | — | $2.94 (+8.80%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $2.94 (−11.79%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $2.94 (−13.86%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $2.94 (−1.76%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $2.94 (+19.74%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $2.94 (+19.74%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $2.94 (−37.17%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $2.94 (−46.88%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $2.94 (−15.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers